L’European society for medical oncology (ESMO) chooses Dr Timothée Olivier, associate physician at the HUG Oncology Department, as co-editor-in-chief for its new scientific journal devoted to rare cancers: EMO Rare Cancers. A prestigious appointment that reflects his expertise in this crucial area of oncology.
Appointed editor-in-chief alongside Dr. Armelle Dufresne of the Center Léon Bérard in Lyon, Dr. Timothée Olivier shares responsibility for the new scientific publication: EMO Rare Cancers. This aims to advance knowledge of rare cancers and the care of the people they affect. Rare cancers, defined by their low incidence (less than 6 cases per 100,000 people per year) pose a particular problem in research leaving significant gaps in knowledge. A paradoxical situation because, although they are individually uncommon, rare cancers together represent up to a quarter of cancer cases.
The appointment of Dr Olivier is part of his clinical specialization for rare tumors, his research work and scientific publications, particularly in the field of sarcomas and cancers of unknown primary (cancer of unknow primary), but also by the specific methodological challenges posed by the study of rare tumors. Methodology is in fact another important area of research for Dr. Olivier.
HUG expertise on rare cancers
Due to their rarity, these cancers require specific expertise, based on clinical experience, a multidisciplinary approach and national or even international collaborations. The HUG Oncology Department has this expertise and makes it available to people suffering from rare cancers. Indeed, the department’s teams are specialized by type of cancer in order to acquire clinical experience in rare cancers in their specialty, as well as an extensive academic research network. For one of the most common rare cancers, sarcoma, the HUG also offers multidisciplinary care thanks to the tumor board sarcome.
A reference review on rare cancers
ESMO, European Society of Medical Oncology, brings together more than 40,000 oncology professionals spread across the world in 177 countries. Its scientific journals are a reference in the field of oncology, and this new publication, EMO Rare Cancerswill be at the forefront in this area.
